Close

KCNJ1 Membrane Protein Introduction

Introduction of KCNJ1

KCNJ1 is encoded by KCNJ1 gene. It belongs to the Potassium Voltage-Gated Channel Subfamily J which has been extensively studied during the past few decades because it offers numerous possibilities for therapeutic applications. It participates in a wide range of biological functions, such as potassium balance and the protection against hypoxia-induced brain injury. KCNJ1 activity is regulated by a variety of kinases and phosphatases. Recent research shows that KCNJ1 variations are associated with multiple diseases, include antenatal Bartter syndrome, thiazide-induced dysglycemia, and diabetes.

Basic Information of KCNJ1
Protein Name ATP-sensitive inward rectifier potassium channel 1
Gene Name KCNJ1
Aliases ROMK1
Organism Homo sapiens (Human)
UniProt ID P48048
Transmembrane Times 2
Length (aa) 391
Sequence MNASSRNVFDTLIRVLTESMFKHLRKWVVTRFFGHSRQRARLVSKDGRCNIEFGNVEAQSRFIFFVDIWTTVLDLKWRYKMTIFITAFLGSWFFFGLLWYAVAYIHKDLPEFHPSANHTPCVENINGLTSAFLFSLETQVTIGYGFRCVTEQCATAIFLLIFQSILGVIINSFMCGAILAKISRPKKRAKTITFSKNAVISKRGGKLCLLIRVANLRKSLLIGSHIYGKLLKTTVTPEGETIILDQININFVVDAGNENLFFISPLTIYHVIDHNSPFFHMAAETLLQQDFELVVFLDGTVESTSATCQVRTSYVPEEVLWGYRFAPIVSKTKEGKYRVDFHNFSKTVEVETPHCAMCLYNEKDVRARMKRGYDNPNFILSEVNETDDTKM

Function of KCNJ1 Membrane Protein

KCNJ1, also named renal outer medullary K+ channel (ROMK), is an ATP-dependent potassium channel in apical membranes of kidney tubules. It plays an important role in lymph pump activity, lymph transport, lymph formation, and the functions of lymph nodes. Previous research has indicated that KCNJ1 variants are significantly related to colorectal adenoma, which suggests it may play a crucial role in tumorigenesis. In addition, studies indicate that KCNJ1 regulates channel activity by reducing expression of KCNJ1 at the cell surface.

Basic structure and Kir channel phylogenetic tree. Fig.1 Basic structure and Kir channel phylogenetic tree.

Application of KCNJ1 Membrane Protein in Literature

  1. Bao M., et al. Genetic screening for Bartter syndrome and Gitelman syndrome pathogenic genes among individuals with hypertension and hypokalemia. Clin Exp Hypertens. 2018. PubMed ID: 29953267

    This article conducts a high-throughput sequencing in patients who suffer from bartter syndrome (BS) and Gitelman syndrome (GS) to investigate the SNP in BS and GS. The results show that KCNJ1 c.941A> G (p.Tyr314Cys) is likely a target for diagnoses and treatment.

  2. Chen B., et al. Novel insights into biomarkers associated with renal cell carcinoma. Oncol Lett. 2018, 16(1): 83-90. PubMed ID: 29928389

    Authors examine the expression level of genes related to Renal cell carcinoma, include (PRKCDBP, EHD2, KCNJ10, ATP1A1, KCNJ1, and EHD2) to identify the prognostic markers and therapeutic targets in RCC. The data indicate that COPS7B may be a biomarker for RCC.

  3. Li X.Y., et al. A clinical and hereditary analysis of novel complex heterozygous KCNJ1 mutation in a Bartter syndrome type II patient. Zhonghua Nei Ke Za Zhi. 2017, 56(10): 760-762. PubMed ID: 29036958

    Authors in this group conduct a case report on Bartter syndrome patients, and the result of DNA sequencing demonstrates that KCNJ1 gene mutations, c. 931C >T (p.R311W) and c. 445-446insCCTGAACAC (p.V149Afs, 150X) could be markers for clinical therapy.

  4. Wu Z.M., et al. The role of estrogen related-receptor γ and ATP-dependent K(+) channel Kcnj1 in renal ischemia-reperfusion injury. Zhonghua Yi Xue Za Zhi. 2017, 97(38): 3017-3021. PubMed ID: 29061011

    This article focuses on the pharmacological role of ERRγ and Kcnj1 in human renal tubular epithelial cells. These results show that ERRγ-Kcnj1 is closely associated with ischemic preconditioning and it is a regulatory factor for protecting the renal ischemia-reperfusion injury.

  5. Guo Z., et al. KCNJ1 inhibits tumor proliferation and metastasis and is a prognostic factor in clear cell renal cell carcinoma. Tumour Biol. 2015, 36(2): 1251-9. PubMed ID: 25344677

    This article evaluates the relationship between KCNJ1 and clear cell renal cell carcinoma. The data illustrate that KCNJ1 could be a target for ccRCC prognosis and treatment.

KCNJ1 Preparation Options

To obtain the soluble and functional target protein, the versatile Magic™ membrane protein production platform in Creative Biolabs enables many flexible options, from which you can always find a better match for your particular project. Aided by our versatile Magic™ anti-membrane protein antibody discovery platform, we also provide customized anti-KCNJ1 antibody development services.


As a forward-looking research institute as well as a leading custom service provider in the field of membrane protein, Creative Biolabs has won good reputation among our worldwide customers for successfully accomplishing numerous challenging projects including generation of many functional membrane proteins. Please feel free to contact us for more information.

Online Inquiry

Verification code
Click image to refresh the verification code.

CONTACT US

45-1 Ramsey Road, Shirley, NY 11967, USA
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356
Email:
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us